1. Mintz GS, et al. Patterns of calcification in coronary artery disease. A statistical analysis of intravascular ultrasound and coronary angiography in 1155 lesions. Circulation. 1995;91(7):1959-65.
        2. Généreux P, et al. J Am Coll Cardiol. 2014;63:1845-54.
        3. Bourantas CV, et al. Heart 2014;100:1158-64.
        4. Chambers, JW & Diage, T. Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions. Expert review of medical devices, 2014;11(5), 457-466.
        5. Dattilo, R, Himmelstein, SI, & Cuff, RF. The COMPLIANCE 360° Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. The Journal of Invasive Cardiology, 2014;26(8),
        6. Shammas, NW, Lam, R, Mustapha, J, Ellichman, J, Aggarwala, G, Rivera, E. & Balar, N. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. Journal of
          Endovascular Therapy, 2012;19(4), 480-488.
        7. Chambers, J, Généreux, P, Lee, A, Lewin, J, Young, C, Crittendon, J & Garrison, LP. The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach. Therapeutic advances in cardiovascular disease, 2016;10(2), 74-85.
        8. Généreux, P, Lee, AC, Kim, CY, Lee, M, Shlofmitz, R, Moses, JW & Chambers, JW. Orbital atherectomy for treating de novo
          severely calcified coronary narrowing (1-year results from the pivotal ORBIT II trial). The American journal of cardiology, 2015;115(12), 1685-1690.
        9. Kashyap, VS, Pavkov, ML, Bishop, PD, Nassoiy, SP, Eagleton, MJ, Clair, DG, & Ouriel, K. Angiography underestimates peripheral atherosclerosis: lumenography revisited. Journal of Endovascular Therapy, 2008;15(1), 117-125.
        10. Chambers, JW, Feldman, RL, Himmelstein, SI, Bhatheja, R, Villa, AE, Strickman, NE & Lee, AC. Pivotal trial to evaluate the safety and efficacy of the orbital atherectomy system in treating de novo, severely calcified coronary lesions (ORBIT II). JACC: Cardiovascular Interventions, 2014;7(5), 510-518.
        11. Weinstock B, Dattilo R, Diage T. Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with
          calcified femoropopliteal lesions. Clinicoecon Outcomes Res. 2014:6 133-139.
        12. Allie, DE, Hebert, CJ, Lirtzman, MD, Wyatt, CH, Keller, VA, Khan, MH, & Allie, SE. Critical limb ischemia: a global epidemic. A critical analysis of current treatment unmasks the clinical and economic costs of CLI. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2005;1(1), 75-84
        13. Yost, ML Peripheral arterial Disease: a report by the Sage Group Accessed June 2017
        14. Yost, ML. The Economic Cost of PAD, CLI & Venous Disease: How Big is the Market?
        15. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics — 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69-e171.
        16. Margolis J et al. Health Care Resources and Costs for Treating Peripheral Artery Disease in a Managed Care Population: Results from Analysis of Administrative Claims Data. J Manag Care Pharm. 2005; 11(9):727-34.
        17. Mahoney, EM, Wang, K, Cohen, DJ, Hirsch, AT, Alberts, MJ, Eagle, K & Bhatt, DL. One-Year Costs in Patients With a History of or at Risk for Atherothrombosis in the United States CLINICAL PERSPECTIVE. Circulation: Cardiovascular Quality and Outcomes, 2008;1(1), 38-45.
        18. Garrison, LP, Lewin, J, Young, CH, Généreux, P, Crittendon, J, Mann, MR, & Brindis, RG. The clinical and cost burden of coronary calcification in a Medicare cohort: an economic model to address under-reporting and misclassification. Cardiovascular Revascularization Medicine, 2015;16(7), 406-412.
        19. Kugelmass, AD, Cohen, DJ, Brown, PP, Simon, AW, Becker, ER, & Culler, SD. Hospital resources consumed in treating complications associated with percutaneous coronary interventions. The American journal of cardiology, 2006;97(3), 322-327.
        20. Go AS, et al. Heart Disease and Stroke Statistics – 2014 Update: A report from the American Heart Association. Circulation. 2014;129:e28 292.
        21. Howlader N, et al. SEER Cancer Statistics Review, 1975-2010. Accessed June 7, 2017.
        22. Schiavetta A, et al. A Phase II Trial of Autologous Transplantation of Bone Marrow Stem Cells for Critical Limb Ischemia: Results of the Naples and Pietra Ligure Evaluation of Stem Cells Study. Stem Cells Transl Med. 2012; 1:572-578.
        23. U.S. Department of Health & Human Services; National Institute of Health; National Heart, Lung, and Blood Institute, August 2006 2011.
        24. Aboyans V, et al. Risk Factors for Progression of Peripheral Arterial Disease in Large and Small Vessels. Circulation. 2006;113:2623-2629.
        25. Graziani L, Piaggesi A. Indications and Clinical Outcomes for Below Knee Endovascular Therapy: Review Article. Catheterization and Cardiovascular Interventions. 2010; 75:433–443.
        26. CDC, NCHS. Underlying Cause of Death 1999-2013 on CDC WONDER Online Database, released 2015. Data are from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed Feb. 3, 2015.
        27. HCUP data on file 2013.
        28. Mustapha, JA, Fisher, BT, Rizzo, JA, Chen, J, Martinsen, BJ, Kotlarz, H, and Gunnarsson, C. Explaining Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease (PAD) Using Decomposition Methods. Journal of Racial and Ethnic Health Disparities, 2017;1-12.
        29. Rizzo, JA, Chen, J, Kotlarz, H, Ryan, MP, & Gunnarsson, C. Racial Disparities in Amputation Rates for the Treatment of Peripheral Artery Disease Using the Health Care Cost and Utilization Project Database. Value in Health, 2016;19(3), A55-A56.
        30. Fitzgerald PJ, et al.. Circulation. 1992;86(1):64-70.
        31. Makam P. J Invasive Cardiol. 2013;25(2):85-8.
        32. Pearce BJ, Toursarkissian B. Diabet Foot Ankle. 2012;3.
        33. Scheinert D. Calcification in the SFA: Clinical Relevance for Acute and Long-Term Outcomes and Treatment Approaches. Presentation at: TCT 2008.
        34. Criqui, M. & Aboyans, V; Circ Res. 2015;116:1509-1526.
        35. Das T, et al., Technique optimization of orbital atherectomy in calcified peripheral lesions of the lower extremities: the CONFIRM series, a prospective multicenter registry.  Catheter Cardiovasc Interv. 2014 Jan 1;83(1):115-22.
        36. Panayiotopoulos YP, Tyrrell MR, Arnold FJ, et al. Results and cost analysis of distal [crural/pedal] arterial revascularisation for limb salvage in diabetic and non-diabetic patients. Diabet Med. 1997;14:214-220
        37. Alonso, A, Garcia, LA. The costs of critical limb ischemia. Endovasc Today, 2011, 32-6.
        38. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update. Circulation, 2016:133(4), e38-e360.
        39. Roger VL, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220.
        40. Warning Signs of a Heart Attack; American Heart Association;; Last reviewed 10/20/2012.
        41. Better Care. Smarter Spending. Healthier People: Paying Providers for Value, Not Volume. CMS Fact Sheet. 2015-01-26. Accessed 8/31/2017.
        42. Where healthcare is now on march to value-based pay. Modern Healthcare. Jan. 28, 2015. Accessed 8/31/2017.
        43. Heart Disease and Stroke Statistics 2017 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2017, January 25,
        44. Mintz, GS. (2015). Intravascular imaging of coronary calcification and its clinical implications. JACC: Cardiovascular Imaging8(4), 461-471.
        45. Babaev A, et al. Orbital Atherectomy Plaque Modification Assessment of the Femoropopliteal Artery Via Intravascular Ultrasound (TRUTH Study). Vasc Endovascular Surg. 2015;49(7):188-94.
        46. Lee M, et al. Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial. Cardiovasc Revasc Med. 2017;18(4):261-264.
        47. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD,, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
        48. Yost M. United States Critical Limb Ischemia by Rutherford Category: Prevalence and Markets in Patients and Limbs. The Sage Group. Beaufort, SC, 2017.
        49. Nehler MR, et al. J Vasc Surg. 2014;60:686-695.
        50. Adams GL, et al. Optimal Techniques with the Diamondback 360 System Achieve Effective Results for the Treatment of Peripheral Artery Disease. J Cardiovasc Transl Res. 2011 Apr; 4(2):220-9
        51. Shlofmitz E, et al. Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. Expert Rev Med Devices. 2017;14(11):867-879.
        52. Yamamoto M, et al. Catheter Cardiovasc Interv. 2018 Oct 17. doi: 10.1002/ccd.27902. [Epub ahead of print]
        53. CSI data on file: based on cadaver atheroschlerotic lesions, porcine coronary lesions and graphite block test models
        54. Allie DE, et al. J Endovasc Ther. 2009;16(Suppl I):I134-I146.
        55. The Sage Group. Accessed January 17, 2020.
        56. Heidenreich PA, et al. Circulation. 2011;123(8):933-944.
        57. Extrapolation of 1-year economic data to 2-year estimates by Brad J. Martinsen, Ph.D. (CSI). Regression analysis with a Power line fit to give predicted 730 day cost offset/savings. Podium Presentation at EuroPCR 2015, Paris and Data on file at CSI.
        58. Shammas N, et al. J Comp Eff Res. 2018;7(4):305-317